Crinetics Pharmaceuticals - CRNX Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRNX shares.
View CRNX analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 12 month target prices for Crinetics Pharmaceuticals' stock. Their CRNX share price forecasts range from $39.00 to $45.00. On average, they predict the company's stock price to reach $42.00 in the next twelve months. This suggests a possible upside of 117.5% from the stock's current price.
View analysts price targets for CRNX or view top-rated stocks among Wall Street analysts.

Crinetics Pharmaceuticals' stock was trading at $18.30 at the beginning of 2023. Since then, CRNX shares have increased by 5.5% and is now trading at $19.31.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our CRNX earnings forecast.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) announced its earnings results on Monday, November, 14th. The company reported ($0.78) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.78). The business earned $0.46 million during the quarter, compared to the consensus estimate of $1 million. Crinetics Pharmaceuticals had a negative trailing twelve-month return on equity of 43.63% and a negative net margin of 2,932.26%.

6 employees have rated Crinetics Pharmaceuticals Chief Executive Officer R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among the company's employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 68.0% of employees surveyed would recommend working at Crinetics Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

(CRNX) raised $80 million in an IPO on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray acted as the underwriters for the IPO.

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

Crinetics Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bourgeon Capital Management LLC (0.00%), Psagot Value Holdings Ltd. Israel (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ajay Madan, Jeff E Knight, Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers, Stephen F Betz and Vivo Capital Viii, Llc.
View institutional ownership trends.

Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRNX stock can currently be purchased for approximately $19.31.

Crinetics Pharmaceuticals (NASDAQ:CRNX) has a market capitalization of $1.04 billion and generates $1.08 million in revenue each year. The company earns $-107,640,000.00 in net income (profit) each year or ($3.00) on an earnings per share basis.

The company employs 143 workers across the globe.

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The official website for the company is www.crinetics.com. The company can be reached via phone at (858) 450-6464 or via email at ir@crinetics.com.